Neuromodulation Devices
•25 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (25)
| Company | Market Cap | Price |
|---|---|---|
|
SYK
Stryker Corporation
OptaBlate BVN system is a neuromodulation/pain-management device.
|
$146.04B |
$381.92
-0.70%
|
|
MDT
Medtronic plc
Neuromodulation Devices cover the spine and brain stimulation technologies (e.g., Inceptiv, Percept) highlighted in the pipeline.
|
$122.56B |
$95.58
-1.17%
|
|
BSX
Boston Scientific Corporation
Neuromodulation devices including Intracept intraosseous nerve ablation system.
|
$107.05B |
$72.19
-2.25%
|
|
GMED
Globus Medical, Inc.
Neuromodulation devices via Nevro spinal cord stimulation platform and expansion.
|
$12.11B |
$90.43
-1.38%
|
|
LIVN
LivaNova PLC
Directly manufactures/distributes Neuromodulation Devices, including VNS Therapy and proximal hypoglossal nerve stimulation systems.
|
$3.56B |
$65.29
-4.59%
|
|
ITGR
Integer Holdings Corporation
Neuromodulation devices are a high-growth served market for Integer and align with its product portfolio.
|
$3.01B |
$86.03
-0.83%
|
|
ATEC
Alphatec Holdings, Inc.
SafeOp neural monitoring systems used during spine surgery.
|
$1.93B |
$13.01
-0.08%
|
|
INSP
Inspire Medical Systems, Inc.
Inspire V is a neuromodulation device designed to treat obstructive sleep apnea, representing Inspire's core product category.
|
$1.87B |
$64.32
-2.25%
|
|
PCRX
Pacira BioSciences, Inc.
IOvera's mechanism relates to neuromodulation/nerve-targeted therapy, aligning with Neuromodulation Devices.
|
$983.47M |
$22.89
+3.57%
|
|
BVS
Bioventus Inc.
Peripheral Nerve Stimulation products (TalisMann, StimTrial) are neuromodulation devices.
|
$700.29M |
$8.48
-2.92%
|
|
AVNS
Avanos Medical, Inc.
The RFA portfolio (ESENTEC, TRIDENT, COOLIEF) places Avanos in the neuromodulation devices category.
|
$644.29M |
$13.91
-0.57%
|
|
BWAY
BrainsWay Ltd.
Core product: BrainsWay's Deep TMS neuromodulation devices.
|
$470.48M |
$12.54
+8.20%
|
|
NPCE
NeuroPace, Inc.
Core product Neuromodulation device (RNS System) delivering brain-responsive, on-demand therapy for drug-resistant epilepsy.
|
$464.64M |
$13.99
+1.16%
|
|
OBIO
Orchestra BioMed Holdings, Inc.
AVIM therapy uses neuromodulation to affect autonomic nervous system responses, fitting Neuromodulation Devices.
|
$236.32M |
$4.38
+1.04%
|
|
CVRX
CVRx, Inc.
CVRx's Barostim is a neuromodulation device (implantable) that modulates the autonomic nervous system via baroreflex activation for heart failure.
|
$222.52M |
$8.51
+4.03%
|
|
NYXH
Nyxoah S.A.
Genio is a neuromodulation implant system (implantable medical device) for obstructive sleep apnea.
|
$147.50M |
$3.92
+4.53%
|
|
STIM
Neuronetics, Inc.
NeuroStar Advanced Therapy System is a non-invasive neuromodulation device; the direct product of the company.
|
$87.95M |
$1.32
+3.94%
|
|
VANI
Vivani Medical, Inc.
Vivani's Neurostimulation division (Cortigent) assets exist and are being spun off, representing Neuromodulation Devices.
|
$74.65M |
$1.30
+3.17%
|
|
ECOR
electroCore, Inc.
Directly markets and sells neuromodulation medical devices (gammaCore, Quell, Truvaga, Sparrow Ascent, TAC-STIM).
|
$60.48M |
$7.96
+4.66%
|
|
NRXS
NeurAxis, Inc.
Core product line: Neuromodulation devices (IB-Stim PENFS).
|
$57.28M |
$5.84
-0.85%
|
|
NMTC
NeuroOne Medical Technologies Corporation
Core product category: neuromodulation devices used to treat epilepsy and pain via brain stimulation and ablation.
|
$33.63M |
$0.67
+0.19%
|
|
COCH
Envoy Medical, Inc.
Cochlear implants operate by neuromodulating auditory pathways, classifying them as neuromodulation devices.
|
$15.06M |
$0.70
+2.15%
|
|
NXL
Nexalin Technology, Inc.
Core product is non-invasive neuromodulation devices for brain stimulation (Gen-2 SYNC, Gen-3 HALO).
|
$7.69M |
$0.45
+0.45%
|
|
AMIX
Autonomix Medical, Inc. Common Stock
Core platform is a catheter-based Neuromodulation Device designed to sense and ablate peripheral nerves.
|
$3.10M |
$0.63
+4.38%
|
|
HSDT
Solana Company
PoNS is a non-invasive neuromodulation device produced by the company for gait and balance rehabilitation.
|
$2.49M |
$2.33
+17.42%
|
Loading company comparison...
Loading industry trends...
Loading research report...
